Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 84, Issue 1, 2013, Pages 106-114

  Beck Broichsitter, Moritz ^a   Rieger, Monika ^a   Reul, Regina ^b   Gessler, Tobias ^a   Seeger, Werner ^a   Schmehl, Thomas ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

"Phase transition release"; Controlled pulmonary drug delivery; In vitro ex vivo correlation; Isolated lung model; Liposomes; Vibrating mesh nebulization

Indexed keywords

1,2 DIPALMITOYL GLYCERO 3 PHOSPHOCHOLINE; 1,2 DIPALMITOYL GLYCERO 3 PHOSPHOETHANOLAMINE; 1,2 DISTEAROYL GLYCERO 3 PHOSPHOCHOLINE; 6 CARBOXYFLUORESCEIN; DYE; FLUORESCENT DYE; LIPOSOME; UNCLASSIFIED DRUG;

ARTICLE; BODY TEMPERATURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG RELEASE; EX VIVO STUDY; FLUORESCENCE SPECTROSCOPY; IN VITRO STUDY; LIPOSOMAL DELIVERY; LUNG; NEBULIZATION; PARTICLE SIZE; TRACHEA;

ABSORPTION; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; FLUORESCEINS; LIPOSOMES; LUNG; MALE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RABBITS;

EID: 84876937843     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.12.003     Document Type: Article

References (42)

1. H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, L.J. Rubin, S. Nikkho, R. Speich, M.M. Hoeper, J. Behr, J. Winkler, O. Sitbon, W. Popov, H.A. Ghofrani, A. Manes, D.G. Kiely, R. Ewert, A. Meyer, P.A. Corris, M. Delcroix, M. Gomez-Sanchez, H. Siedentop, and W. Seeger Inhaled iloprost for severe pulmonary hypertension N. Engl. J. Med. 347 2002 322 329
2. T. Gessler, W. Seeger, and T. Schmehl Inhaled prostanoids in the therapy of pulmonary hypertension J. Aerosol Med. 21 2008 1 12
3. T. Gessler, W. Seeger, and T. Schmehl The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension Ther. Adv. Respir. Dis. 5 2011 195 206
4. B.D. Kurmi, J. Kayat, V. Gajbhiye, R.K. Tekade, and N.K. Jain Micro- and nanocarrier-mediated lung targeting Expert Opin. Drug Deliv. 7 2010 781 794
5. T. Lebhardt, S. Roesler, M. Beck-Broichsitter, and T. Kissel Polymeric nanocarriers for drug delivery to the lung J. Drug Deliv. Sci. Technol. 20 2010 171 180
6. M. Beck-Broichsitter, O.M. Merkel, and T. Kissel Controlled pulmonary drug and gene delivery using polymeric nano-carriers J. Control. Release 161 2012 214 224
7. M.M. Gaspar, U. Bakowsky, and C. Ehrhardt Inhaled liposomes-current strategies and future challenges J. Biomed. Nanotechnol. 4 2008 245 257
8. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160
9. E. Elizondo, E. Moreno, I. Cabrera, A. Cordoba, S. Sala, J. Veciana, and N. Ventosa Liposomes and other vesicular systems: structural characteristics, methods of preparation, and use in nanomedicine Prog. Mol. Biol. Transl. Sci. 104 2011 1 52
10. A. Wagner, K. Vorauer-Uhl, and H. Katinger Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer J. Liposome Res. 16 2006 113 125
11. A.M.A. Elhissi, M. Faizi, W.F. Naji, H.S. Gill, and K.M.G. Taylor Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures Int. J. Pharm. 334 2007 62 70
12. E. Kleemann, T. Schmehl, T. Gessler, U. Bakowsky, T. Kissel, and W. Seeger Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability Pharm. Res. 24 2007 277 287
13. M.M. Gaspar, O. Gobbo, and C. Ehrhardt Generation of liposome aerosols with the Aeroneb Pro and the AeroProbe nebulizers J. Liposome Res. 20 2010 55 61
14. A.M.A. Elhissi, J. Giebultowicz, A.A. Stec, P. Wroczynski, W. Ahmed, M.A. Alhnan, D. Phoenix, and K.M.G. Taylor Nebulization of ultradeformable liposomes: the influence of aerosolization mechanism and formulation excipients Int. J. Pharm. 436 2012 519 526
15. S. Anabousi, E. Kleemann, U. Bakowsky, T. Kissel, T. Schmehl, T. Gessler, W. Seeger, C.M. Lehr, and C. Ehrhardt Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant J. Nanosci. Nanotechnol. 6 2006 3010 3016
16. M. Zaru, S. Mourtas, P. Klepetsanis, A.M. Fadda, and S.G. Antimisiaris Liposomes for drug delivery to the lungs by nebulization Eur. J. Pharm. Biopharm. 67 2007 655 666
17. J.N. Weinstein, R.D. Klausner, T. Innerarity, E. Ralston, and R. Blumenthal Phase transition release, a new approach to the interaction of proteins with lipid vesicles. Application to lipoproteins Biochim. Biophys. Acta 647 1981 270 284
18. C. Beaulac, S. Clement-Major, J. Hawari, and J. Lagace In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition J. Microencapsulation 14 1997 335 348
19. R. Karki, G. Subramanya, and N. Udupa Formulation and evaluation of coencapsulated rifanpicin and isoniazid liposomes using different lipids Acta Pharm. Sci. 51 2009 177 188
20. A.C. Santos, C.M. Matos, B. Oliveiros, T. Almeida, L. Gano, M. Neves, and N. Ferreira Thermolabile liposomes: a controlled release delivery tool in diagnosis/therapy in experimental pulmonary oedema Curr. Radiopharm. 5 2012 166 174
21. M. Sakagami In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery Adv. Drug Deliv. Rev. 58 2006 1030 1060
22. R.U. Agu, and M.I. Ugwoke In vitro and in vivo testing methods for respiratory drug delivery Expert Opin. Drug Deliv. 8 2011 57 69
23. M. Beck-Broichsitter, T. Schmehl, W. Seeger, and T. Gessler Evaluating the controlled release properties of inhaled nanoparticles using isolated, perfused, and ventilated lung models J. Nanomater. 2011 (Article ID 163791)
24. W. Seeger, D. Walmrath, F. Grimminger, S. Rosseau, H. Schutte, H.J. Kramer, L. Ermert, and L. Kiss Adult respiratory distress syndrome: model systems using isolated perfused rabbit lungs Methods Enzymol. 233 1994 549 584
25. K. Lahnstein, T. Schmehl, U. Ruesch, M. Rieger, W. Seeger, and T. Gessler Pulmonary absorption of aerosolized fluorescent markers in the isolated rabbit lung Int. J. Pharm. 351 2008 158 164
26. M. Beck-Broichsitter, J. Gauss, C.B. Packhaeuser, K. Lahnstein, T. Schmehl, W. Seeger, T. Kissel, and T. Gessler Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model Int. J. Pharm. 367 2009 169 178
27. M. Beck-Broichsitter, J. Gauss, T. Gessler, W. Seeger, T. Kissel, and T. Schmehl Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles J. Aerosol Med. 23 2010 47 57
28. J.P. Mitchell, M.W. Nagel, S. Nichols, and O. Nerbrink Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers J. Aerosol Med. 19 2006 409 433
29. C. Jafaar-Maalej, V. Andrieu, A. Elaissari, and H. Fessi Assessment methods of inhaled aerosols: technical aspects and applications Expert Opin. Drug Deliv. 6 2009 941 959
30. L.A. Dailey, E. Kleemann, M. Wittmar, T. Gessler, T. Schmehl, C. Roberts, W. Seeger, and T. Kissel Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA Pharm. Res. 20 2003 2011 2020
31. L.A. Dailey, T. Schmehl, T. Gessler, M. Wittmar, F. Grimminger, W. Seeger, and T. Kissel Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features J. Control. Release 86 2003 131 144
32. M. Beck-Broichsitter, P. Kleimann, T. Gessler, W. Seeger, T. Kissel, and T. Schmehl Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb® Pro: formulation aspects and nanoparticle stability to nebulization Int. J. Pharm. 422 2012 398 408
33. M. Gibaldi, and D. Perrier Pharmakokinetics 1982 Marcel Dekker New York
34. J. Behr, G. Zimmermann, R. Baumgartner, H. Leuchte, C. Neurohr, P. Brand, C. Herpich, K. Sommerer, J. Seitz, G. Menges, S. Tillmanns, and M. Keller Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation J. Aerosol Med. 22 2009 121 129
35. O.B. Garbuzenko, M. Saad, S. Betigeri, M. Zhang, A.A. Vetcher, V.A. Soldatenkov, D.C. Reimer, V.P. Pozharov, and T. Minko Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug Pharm. Res. 26 2009 382 394
36. M. Murata, K. Nakano, K. Tahara, Y. Tozuka, and H. Takeuchi Pulmonary delivery of elatonin using surface-modified liposomes to improve systemic absorption: polyvinyl alcohol with a hydrophobic anchor and chitosan oligosaccharide as effective surface modifiers Eur. J. Pharm. Biopharm. 80 2012 340 346
37. K.M.G. Taylor, and R.M. Morris Thermal analysis of phase transition behavior in liposomes Thermochim. Acta 248 1995 289 301
38. A.S. Ulrich Biophysical aspects of using liposomes as delivery vehicles Biosci. Rep. 22 2002 129 150
39. J. Heyder Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery Proc. Am. Thorac. Soc. 1 2004 315 320
40. T.C. Carvalho, J.I. Peters, and R.O. Williams III Influence of particle size on regional lung deposition: What evidence is there? Int. J. Pharm. 406 2011 1 10
41. E. Rytting, M. Bur, R. Cartier, T. Bouyssou, X. Wang, M. Krueger, C.M. Lehr, and T. Kissel In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles J. Control. Release 141 2010 101 107
42. Y. Lu, S.W. Kim, and K. Park In vitro-in vivo correlation: perspectives on model development Int. J. Pharm. 418 2011 142 148